News

Medpace Logo

For Immediate Release: March 29, 2017

Contact
Mary Kuramoto
513-579-9911 x 12523
m.kuramoto@medpace.com

Dr. Douglas Lee Joins Medpace as Senior Medical Director

CINCINNATI, OH — (March 29, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Douglas Lee has joined Medpace as Senior Medical Director of Medical Affairs. Dr. Lee is an experienced drug developer with about 20 years of experience in both clinical medicine and drug development. He joins a team of physicians at Medpace that provide specialized expertise throughout the design and execution of a Sponsor’s program which results in a distinct advantage through greater depth of knowledge and hands-on leadership.

About Douglas Lee, MB BCh, MRCP, MBA
Dr. Douglas Lee is a seasoned Pharmaceutical Physician with therapeutic expertise in areas such as cardiovascular/metabolic (CVM), gastrointestinal (GI) and inflammatory diseases. Prior to joining Medpace, Dr. Lee was the Global Senior Medical Director for a large pharmaceutical company where he designed, oversaw and executed global development plans involving early and late phase assets. In 2012 -13, he led a team that gained Marketing Authorization Approval (MAA) for 3 diabetes products, under the European Centralized Procedure. Dr. Lee received his Bachelor of Medicine, Bachelor of Surgery at the Queens University Medical School in the United Kingdom (UK) and achieved his Membership of the Royal College of Physicians in UK. He also earned his MBA from the Imperial College London in 2013.

About MEDPACE
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious diseases, and neurology and psychiatry.